More articles from Cancer Diagnosis and Management

  • The rationale for, and design of, a lung cancer screening program
    Peter Mazzone, MD, MPH and
    Cleveland Clinic Journal of Medicine May 2012, 79 (5) 337-345; DOI: https://doi.org/10.3949/ccjm.79a.12018

    We are entering a new era in which lung cancer screening may be considered the standard of care.

  • Managing cancer pain: Frequently asked questions
    Raghava R. Induru, MD and Ruth L. Lagman, MD, MPH, FACP
    Cleveland Clinic Journal of Medicine July 2011, 78 (7) 449-464; DOI: https://doi.org/10.3949/ccjm.78a.10054

    Cancer pain: its pathogenesis, how to assess it, and how to treat it—in particular, how to use opioids optimally.

  • A practical guide to prostate cancer diagnosis and management
    A practical guide to prostate cancer diagnosis and management
    Matthew N. Simmons, MD, PhD, Ryan K. Berglund, MD and J. Stephen Jones, MD
    Cleveland Clinic Journal of Medicine May 2011, 78 (5) 321-331; DOI: https://doi.org/10.3949/ccjm.78a.10104

    Screening, diagnosis, and management of prostate cancer can be complicated, with no clear consensus about key issues. Our approach refl ects the guidelines from the American Urological Association.

  • Malignant bowel obstruction: Individualized treatment near the end of life
    Aileen Soriano, MD and Mellar P. Davis, MD
    Cleveland Clinic Journal of Medicine March 2011, 78 (3) 197-206; DOI: https://doi.org/10.3949/ccjm.78a.10052

    Surgery should not be routinely done. Less-invasive approaches such as gastric and colonic stenting are useful.

  • Symptom management: An important part of cancer care
    Laura K. Shoemaker, DO, Bassam Estfan, MD, Raghava Induru, MD and T. Declan Walsh, MD
    Cleveland Clinic Journal of Medicine January 2011, 78 (1) 25-34; DOI: https://doi.org/10.3949/ccjm.78a.10053

    In addition to diagnosing and managing the cancer itself, the physician’s duty is also to recognize and effectively manage the many associated symptoms.

  • Prostate-specific antigen: How to advise patients as the screening debate continues
    Peter C. Albertsen, MD, MS
    Cleveland Clinic Journal of Medicine June 2005, 72 (6) 521-527;

    There is still no consensus on whether prostate-specific antigen measurement should be used as a screening test for prostate cancer, but patients have the right to be informed about its risks and possible benefits.

  • Cancer pain: How to measure the fifth vital sign
    Mellar P. Davis, MD and Declan Walsh, MSc
    Cleveland Clinic Journal of Medicine August 2004, 71 (8) 625-632;

    To control pain effectively in cancer patients, we must assess it regularly and consistently.

  • Progress in preventing chemotherapy-induced nausea and vomiting
    Cleveland Clinic Journal of Medicine August 2002, 69 (8) 609-617;

    Our understanding of the pathophysiology of emesis has improved, and we now have drugs that can prevent acute emesis in most patients. Delayed and anticipatory emesis remain a challenge.

  • Malignant melanoma: Treatments emerging, but early detection is still key
    Paul Masci, DO and Ernest C. Borden, MD
    Cleveland Clinic Journal of Medicine July 2002, 69 (7) 529-545;

    Interferon alfa-2b can increase disease-free survival in malignant melanoma, but we can have far more impact by detecting this disease earlier and by teaching patients how to recognize and possibly avoid it.

  • Assessing cancer clinical trials: Will your patient benefit from a ‘breakthrough’?
    Cleveland Clinic Journal of Medicine May 2002, 69 (5) 368-376;

    Pick up a newspaper or turn on the news, and you will see a story about some breakthrough in cancer. So will your patients.

Pages